echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The effect of intestinal flora and nerve inflammation, China's original new drug "Phase 9 One" International Multi-Center III clinical trial launched.

    The effect of intestinal flora and nerve inflammation, China's original new drug "Phase 9 One" International Multi-Center III clinical trial launched.

    • Last Update: 2020-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Alzheimer's disease (i.e., Alzheimer's disease) is a degenerative lesions of the central nervous system that occurs in early and early age, mainly characterized by cognitive decline and behavioral impairment, such as inability to eat autonomously, memory disorders or complete relics, and are also accompanied in part by aphasia and visual impairment.
    , the number of People with Alzheimer's disease in China is expected to exceed 10 million, with an average of 3.5 out of every 1,000 people, and that proportion is likely to continue to increase as the aging of the Chinese population progresses.
    the current drug treatment for Alzheimer's disease is mainly on the treatment of the disease, and there are not many drugs available to delay or prevent progression.
    November 2, 2019, the National Drug Administration approved a listing application for the original new drug for Alzheimer's disease, "Phase 9 One" (Glynette Sodium, code name: GV-971), "for mild to moderate Alzheimer's disease and to improve patients' cognitive function."
    the development of this new AD drug is thought to be a different way, disruptive to reveal a new mechanism of anti-AD pathogenesis targeting the brain intestine axis. the emergence of
    "GV-971 provides a direction and means to promote basic research.
    " neuroscientist zhang Xu, a member of the Chinese Academy of Sciences, said it may be the main pathway for neurodegenerative diseases, and the implication is that the metabolic system and the immune system can influence the brain through the action of the brain's intestinal axis.
    Phase 9 Phase 1" improves cognitive decline by reshaping the balance of intestinal flora, inhibiting the abnormal increase of specific metabolites of intestinal flora, reducing peripheral and central inflammation, and reducing beta amyloid protein deposition and Tau protein overphosation.
    as the first anti-AD drug in China to conduct a large-scale phase III clinical trial, and the first new drug for the treatment of Alzheimer's disease in the world. the advent of the
    Phase 1 of the ninth issue has brought new hope to countless people with Alzheimer's disease and their families.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.